Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
About
Degron Therapeutics develops novel molecular glue degrader (MGD) drugs using its proprietary GlueXplorer® platform to target historically intractable disease targets. This platform leverages a large, structurally differentiated compound library and advanced screening systems to address the challenges of rational MGD design. The company aims to "drug the undruggable" by creating new therapeutic options for diseases.
Tags
Total Employees
24
Current headcount
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Degron Therapeutics do?
Degron Therapeutics develops novel molecular glue degrader (MGD) drugs using its proprietary GlueXplorer® platform to target historically intractable disease targets. This platform leverages a large, structurally differentiated compound library and advanced screening systems to address the challenges of rational MGD design. The company aims to "drug the undruggable" by creating new therapeutic options for diseases. (formerly [].)
How much funding has Degron Therapeutics raised?
Degron Therapeutics has raised a total of $185M in funding. The most recent round on record is Series A Extension.
Where is Degron Therapeutics headquartered?
Degron Therapeutics is headquartered in San Diego, California, USA.
When was Degron Therapeutics founded?
Degron Therapeutics was founded in 2020.
What industry does Degron Therapeutics operate in?
Degron Therapeutics operates in Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare, Biotech, Clinical Trials.
How many employees does Degron Therapeutics have?
Degron Therapeutics has approximately 24 people on record.
Similar Startups